Search clinical trials for: STX209 (arbaclofen)

Total 168 results

Seaside Therapeutics, Inc.

Terminated

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Timothy Roberts
Simons Foundation; Clinical Research Associates, LLC

Completed

MEG Study of Acute STX209 Effects in ASD

Autism Disorder

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (Harbor-A)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)

Fragile X Syndrome

United States
Celso Arango, MD, PhD
UMC Utrecht

Completed

Arbaclofen in Children and Adolescents With ASD (AIMS2-CT1)

Autism Spectrum Disorder

Spain, United Kingdom, France
Seaside Therapeutics, Inc.

Completed

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Clinical Research Associates, LLC

Recruiting

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

16P11.2 Deletion Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

Fragile X Syndrome

United States
Indivior Inc.

Completed

A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers

Healthy Volunteers

United Kingdom
XenoPort, Inc.

Completed

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

Back Pain

United States
XenoPort, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States, Canada
XenoPort, Inc.

Completed

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Multiple Sclerosis

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
King's College London

Completed

Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United Kingdom
Evdokia Anagnostou
McMaster University; Unity Health Toronto; University of Toronto; University of... and other collaborators

Active, not recruiting

Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) (ARBA)

Autism Spectrum Disorder

Canada
Gonzalez-Heydrich, Joseph, M.D.
Boston Children's Hospital; Seaside Therapeutics, Inc.

Terminated

TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers

Autism

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
RVL Pharmaceuticals, Inc.

Not yet recruiting

A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Spasticity
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
Astex Pharmaceuticals, Inc.

Recruiting

Study of ASTX029 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States, France, Spain, United Kingdom
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Leadiant Biosciences, Inc.

Completed

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

Necrotizing Enterocolitis

United States
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
Seaside Therapeutics, Inc.

Suspended

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

Fragile X Syndrome

United States
XenoPort, Inc.

Completed

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Gastroesophageal Reflux

United States
Leadiant Biosciences, Inc.

Completed

Safety and Tolerability of STP206 in Healthy Adult Subjects

Healthy

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Astex Pharmaceuticals, Inc.

Completed

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Healthy Volunteers

United States
Seaside Therapeutics, Inc.
National Institutes of Health (NIH)

Completed

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

Fragile X Syndrome

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
Tanta University

Unknown

Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis

Liver Cirrhosis | Muscle Cramps

Egypt
National Institute of Mental Health (NIMH)

Completed

Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain

mGluR5 Receptors

United States
H. Lee Moffitt Cancer Center and Research Institute
Endo Pharmaceuticals

Completed

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

United States
Endo Pharmaceuticals

Completed

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) (Bladder Cancer)

Carcinoma in Situ | Bladder Cancer

United States
Indivior Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

GERD

United States
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
Sangamo Therapeutics

Active, not recruiting

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients (STEADFAST)

End Stage Renal Disease | Kidney Transplant Rejection

Belgium, Netherlands, United Kingdom
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
University of Minnesota
Paralyzed Veterans of America Research Foundation

Completed

Oral and IV Baclofen in Adult Volunteers

Baclofen Withdrawal Syndrome

United States
Allaysis, LLC
University of Minnesota

Unknown

Repeated Dose IV Baclofen Safety/Bioequivalence Study

Intravenous Baclofen

3

Subscribe